Daily news about corporate social responsibility, ethics and sustainability
Tags (2) : immunology
Harbour BioMed Reports Positive Phase I Results for HBM9378 Antibody Therapy
03/23/2026 | Companies
antibody therapeutics,
biologics,
biotech innovation,
chronic obstructive pulmonary disease,
clinical research,
COPD,
drug development,
half-life extension,
Harbour BioMed,
HBM9378,
immune-oncology,
immunological disorders,
immunology,
Kelun-Biotech,
monoclonal antibody,
pharmacokinetics,
Phase I clinical trial,
respiratory medicine,
safety profile,
severe asthma,
SKB378,
TSLP inhibitor,
WIN378
Companies
Most Popular Now
Environment News
Compliance
Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com